Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4486 | Ordered by Date (descending)
next pagenext page 1 2 3 4 5 ... 43 44 45  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Danish National Genome Center–Qiagen: genomic software tools, 202306– supply QCI Interpret software for oncology genome sequencing by Qiagen 2023-06-13
Dynamic42–OTHER: investment, 202306 financing round Series A totalling mid-7-figure € incl a family office from the health sector 2023-06-13
Dynamic42–SEVERAL: investment, 202306 financing round Series A mid-7-figure € incl investors bm-t + a familly office 2023-06-13
Dynamic42–Thuringia (govt): investment, 202306 financing round Series A totalling mid-7-figure € incl existing investor bm-t 2023-06-13
Chinook Therapeutics–Novartis: investment, 202306– acquisition $3.2b cash upfront + $300m cash milestones of Chinook by Novartis ANNOUNCED 2023-06-12
Upstream Bio–SEVERAL: investment, 202306 financing round Series B $200m co-led by Enavate Sciences + Venrock Healthcare Capital Partners 2023-06-08
OntoChem–Holtzbrinck: investment, 202306 acquisition 100% of OntoChem by Digital Science 2023-06-07
Bayer–Acuitas Therapeutics: LNP technology, 202306– collab €na using LNP technology to deliver RNA payloads to liver 2023-06-05
ITM–SEVERAL: investment, 202306 financing round €255m led by Temasek 2023-06-05
Sartorius–Waters: biopharma production technology, 202306– collab expansion integration of PATROL UPLC PAS with Resolute BioSMB platform 2023-06-05
4Pharma–BC Platforms: investment, 202306 acquisition €na of 4Pharma by BC Platforms 2023-06-01
Bico–Swiss Life: real estate, 202306– leaseback 15y of property in Berlin by Scienion from BEOS Light Industrial Germany I fund 2023-06-01
Swiss Life–Bico: real estate, 202306 acquisition €21m of new Scienion property in Berlin by BEOS Light Industrial Germany I fund 2023-06-01
Synaffix–Lonza: investment, 202306 acquisition €100m upfront cash + €60m milestones of Synaffix by Lonza 2023-06-01
Theragnostics–Ariceum Therapeutics: investment, 202306 acquisition 100% of Theragnostics Ltd for $2.5m cash upfront plus $41.5m milestones 2023-06-01
Hookipa–SEVERAL: investment, 202305 public offering $50m with 22.9m common stock at $1.31/share plus 15,268 Series A-2 preferred stock at $1.310/each 2023-05-31
Mithra Pharmaceuticals–BioConfidant: public relations, 202305 service existent by Cohesion Bureau 2023-05-29
CARTemis Therapeutics–Germany (govt): grant, 202305– BMBF grant €4.6m to develop CAR T-cell therapy targeting CXCR5 (to MDC+Charité) 2023-05-26
Michor Consulting–QbD Group: investment, 202305 acquisition of Michor Consulting by QbD Group 2023-05-25
Prosion–10xDNA: investment, 202205 existent 7-figure seed investment by 10xDNA 2023-05-23
Smartbax–Boehringer: investment, 202305 seed financing round totalling €1.2m incl existing investor BIVF 2023-05-23
Smartbax–High-Tech Gründerfonds: investment, 202305 seed financing round totalling €1.2m incl new investor HTGF 2023-05-23
Smartbax–SEVERAL: investment, 202305 seed financing round €1.2m from BIVF + HTGF 2023-05-23
Smartbax–Trophic Communications: public relations, 202305 service existent by Trophic 2023-05-23
Oncimmune–Freenome: investment, 202305 acquisition of Oncimmune Ltd by Freenome 2023-05-22
VectivBio–Ironwood: investment, 202305–202306 acquisition $1b net of cash/debt cash tender offer at $17/share 2023-05-21
Traceless Materials–Germany (govt): grant, 202305– BMUV funding €5.1m for construction of demonstration plant 2023-05-19
Boundless Bio–Bayer: investment, 202305 financing round Series C totalling $100m incl new + co-lead investor Leaps by Bayer 2023-05-16
Boundless Bio–Nextech: investment, 202305 financing round Series C totalling $100m incl existing + co-investor Nextech Invest 2023-05-16
Boundless Bio–SEVERAL: investment, 202305 financing round Series C $100m co-led by Leaps by Bayer + RA Capital 2023-05-16
Boundless Bio–Sophia Genetics: molecular diagnostics, 202305 existent collab develpm ecDNA Harboring Oncogenes clinical trial assay ECHO for BBI-355 2023-05-16
Dualyx–High-Tech Gründerfonds: investment, 202305 financing round Series A totalling €40m incl existing + co-investor HTGF 2023-05-15
Dualyx–SEVERAL: investment, 202305 financing round Series A €40m co-led by Fountain Heathcare Partners + Forbion + Andera Partners 2023-05-15
Exazyme–AIX Ventures: investment, 202305 seed financing round totalling €2m from AIX Ventures + Atlantic Labs 2023-05-15
Exazyme–Altantic Labs: investment, 202305 seed financing round totalling €2m from AIX Ventures + Atlantic Labs 2023-05-15
Exazyme–SEVERAL: investment, 202305 seed financing round €2m from AIX Ventures + Atlantic Labs 2023-05-15
Nia Health–Adesso: investment, 202305 seed financing round totalling €3.5m incl co-investor Adesso Ventures 2023-05-15
Nia Health–High-Tech Gründerfonds: investment, 202305 seed financing round totalling €3.5m incl lead investor HTGF 2023-05-15
Nia Health–PERSON: investment, 202305 seed financing round totalling €3.5m incl co-investor fund of Kurt Schwarz 2023-05-15
Nia Health–Piabo PR: public relations, 202305 service existent by Piabo PR 2023-05-15
Nia Health–SEVERAL: investment, 202305 seed financing round €3.5m led by HTGF 2023-05-15
Nia Health–Ventura BioMed Investors: investment, 202305 seed financing round totalling €3.5m incl co-investor Venture BioMed Investors 2023-05-15
Repare Therapeutics–Vivlion: gene editing, 202305– supply of PRICSR CRISPR gRNA libraries for synthetic lethal screening by Vivlion 2023-05-11
UCB–Ariceum Therapeutics: targeted radiopharmaceuticals, 202305– collab strategic r+d for TRTs for solid tumours + immune-related diseasees 2023-05-11
Bayer–Bicycle Therapeutics: Bicycle technology, 202305– strategic collab $45m upfront + $1.7b milestones for targeted radiopharmaceuticals 2023-05-10
DiogenX–AdBio Partners: investment, 202305 financing round Series A totalling €27.5m incl existing + co-investor AdBio Partners 2023-05-10
DiogenX–Boehringer: investment, 202305 financing round Series A totalling €27.5m incl existing + co-lead investor Boehringer Ingelheim Venture Fund 2023-05-10
DiogenX–Juvenile Diabetes Research Foundation: investment, 202305 financing round Series A totalling €27.5m incl existing + co-investor JDRF T1D Fund 2023-05-10
DiogenX–Lilly: investment, 202305 financing round Series A totalling €27.5m incl new + co-investor Eli Lilly 2023-05-10
DiogenX–Omnes Capital: investment, 202305 financing round Series A totalling €27.5m incl new + co-investor Omnes 2023-05-10
DiogenX–Roche: investment, 202305 financing round Series A totalling €27.5m incl new + co-lead investor Roche Venture Fund 2023-05-10
DiogenX–SEVERAL: investment, 202305 financing round Series A €27.5m led by BIVF + Roche Venture Fund 2023-05-10
Ascend GCTx–4BIO Ventures: investment, 202305c financing round Series A incl co-investor 4BIO Capital 2023-05-09
Ascend GCTx–Ajinomoto: investment, 202305c financing round Series A incl co-investor Ajinomoto Co Inc 2023-05-09
Ascend GCTx–Carlyle: investment, 202305c financing round Series A incl co-lead investor Abingworth 2023-05-09
Ascend GCTx–Cathay Capital: investment, 202305c financing round Series A incl co-investor Cathay Health 2023-05-09
Ascend GCTx–DCVC: investment, 202305c financing round Series A incl co-investor DCVC Bio 2023-05-09
Ascend GCTx–Deerfield: investment, 202305c financing round Series A incl co-investor Deerfield Management 2023-05-09
Ascend GCTx–Digitalis Ventures: investment, 202305c financing round Series A incl co-investor Digitalis Ventures 2023-05-09
Ascend GCTx–Petrichor Healthcare: investment, 202305c financing round Series A incl co-lead investor Petrichor 2023-05-09
Ascend GCTx–Ramarketing: public relations, 202305 service existent Ramarketing is media contact 2023-05-09
Ascend GCTx–SEVERAL: investment, 202305c financing round Series A bringing total raised to $132.5m led by Abingworth + Petrichor 2023-05-09
Cambridge Research Biochemicals–Biosynth: investment, 202305 acquisition of CRB by Biosynth 2023-05-09
PolyPeptide–Numaferm: peptide synthesis, 202305– collab €na Preferred Partner Collaboration Agreement for peptide development + production 2023-05-09
Roche–Zion Pharma: tyrosine kinase inhibitor, 202305– acqisition ww rights $70m ufpront + near-term MS + $610m milestones + royalties to ZN-A-1041 2023-05-09
Midwest Biosolutions–Bionter: analytical instruments, 202305– collab Midwest Bio to promote + sell Bionter products + services in the US 2023-05-08
Zontal–Bruker: investment, 202305 acquisition €na of Zontal by Bruker 2023-05-08
Bicycle Therapeutics–Helmholtz: Bicycle radio conjugates, 202305– collab to discovery + develop BRCs for a range of oncology targets with DKFZ 2023-05-04
Anavo Therapeutics–ABP (NL): investment, 202305 seed financing round extenstion totalling €8.5m incl existing investor Inkef Capital 2023-05-02
Anavo Therapeutics–Bioqube Ventures: investment, 202305 seed financing round extenstion totalling €8.5m incl existing investor Bioqube Ventures 2023-05-02
Anavo Therapeutics–Merck (DE): investment, 202305 seed financing round extenstion totalling €8.5m incl existing investor M Ventures 2023-05-02
Anavo Therapeutics–Merck (US): investment, 202305 seed financing round extenstion totalling €8.5m incl new investor MRL Ventures Fund 2023-05-02
Anavo Therapeutics–Otsuka: investment, 202305 seed financing round extenstion totalling €8.5m incl existing investor Taiho Ventures 2023-05-02
Anavo Therapeutics–SEVERAL: investment, 202305 seed financing round extenstion €8.5m with new investor MRL Ventures + all existing investors 2023-05-02
Medigene–Helmholtz: cancer immunotherapy, 202305– license ww excl to CD40L-CD28 costimulatory swith receptor from Helmholtz Munich 2023-05-02
Ten23 Health–Bionter: particle counting, 202305– collab developm of methods incl installation of EVE particle counter at Ten23 Heatlh 2023-05-02
VectivBio–Forbion: investment, 202305 existent shareholder Forbion 2023-05-01
Clickmer Systems–APIS Assay Technologies: investment, 202204 acquisition of Clickmer Systems for single-digit €m by APIS Assay Technologies Ltd 2023-04-25
Forbion–SEVERAL: investment, 202304 final close of Forbion Growth Opportunities Fund II with addit €130m bringing total fund size to hard cap €600m 2023-04-19
Forbion–SEVERAL: investment, 202304 final close €750m of Forbion Ventures Fund VI 2023-04-19
Gilde Investment–SEVERAL: investment, 202304 announced new Gilde Healthcare Venture&Growth VI with €600m investor commitments 2023-04-19
Ariceum Therapeutics–Andera Partners: investment, 202304 financing round Series A extension totalling €22.75m incl new + co-lead investor Andera 2023-04-18
Ariceum Therapeutics–Bellevue: investment, 202304 financing round Series A extension totalling €22.75m incl existing + co-investor Pureos Bioventures 2023-04-18
Ariceum Therapeutics–Earlybird: investment, 202304 financing round Series A extension totalling €22.75m incl new + co-lead investor Earlybird VC 2023-04-18
Ariceum Therapeutics–SEVERAL: investment, 202304 financing round Series A extension €22.75m bringing total Series A to €47.75m 2023-04-18
Zetta Genomics–Apex Ventures: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Apex Ventures 2023-04-18
Zetta Genomics–SEVERAL: investment, 202304 2nd seed financing round £1.9m with led by Nina Capital 2023-04-18
Zetta Genomics–Univ Cambridge: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Cambridge Enterprise 2023-04-18
Bio-Techne–Lunaphore: spatial omics, 202304– collab strategic partnership integrating COMET system with RNAscope technology 2023-04-17
Complement Therapeutics–BioGeneration Ventures: investment, 202304 financing round Series A totalling €72m incl exising + co-investor BGV 2023-04-17
Complement Therapeutics–Cambridge Innovation Capital: investment, 202304 financing round Series A totalling €72m incl new + co-investor CIC 2023-04-17
Complement Therapeutics–Forbion: investment, 202304 financing round Series A totalling €72m incl exising + co-lead investor Forbion 2023-04-17
Complement Therapeutics–Gimv: investment, 202304 financing round Series A totalling €72m incl new + lead investor Gimv 2023-04-17
Complement Therapeutics–Hadean Ventures: investment, 202304 financing round Series A totalling €72m incl new + co-investor Hadean Ventures 2023-04-17
Complement Therapeutics–Panakès Partners: investment, 202304 financing round Series A totalling €72m incl new + co-investor Panakès Partners 2023-04-17
Complement Therapeutics–Seroba: investment, 202304 financing round Series A totalling €72m incl new + co-investor Seroba Life Sciences 2023-04-17
Complement Therapeutics–SEVERAL: investment, 202304 financing round Series A €72m led by new investor Gimv 2023-04-17
Syngenta–Ginkgo Bioworks: seed technology, 202304– collab research using protein engineering + uHTS technologies to design + develop new plant traits 2023-04-17
CellPhenomics–Kyan Therapeutics: drug development technology, 202304– collab combi Optim.AI technology with PD3D technology for drug development 2023-04-14
Alentis Therapeutics–Bellevue: investment, 202304 financing round Series C totalling $105m incl existing + co-investor BB Pureos Bioventures 2023-04-13
next pagenext page 1 2 3 4 5 ... 43 44 45  next pagenext page



Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner Voices Peter Seeberger Chemistry Transformation 650x300px

» top